VTv Therapeutics Net Worth
VTv Therapeutics Net Worth Breakdown | VTVT |
VTv Therapeutics Net Worth Analysis
VTv Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including VTv Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of VTv Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform VTv Therapeutics' net worth analysis. One common approach is to calculate VTv Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares VTv Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing VTv Therapeutics' net worth. This approach calculates the present value of VTv Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of VTv Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate VTv Therapeutics' net worth. This involves comparing VTv Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into VTv Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if VTv Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding VTv Therapeutics' net worth research are outlined below:
| vTv Therapeutics generated a negative expected return over the last 90 days | |
| vTv Therapeutics has high historical volatility and very poor performance | |
| vTv Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 9 K. Net Loss for the year was (20.25 M) with loss before overhead, payroll, taxes, and interest of (9.93 M). | |
| vTv Therapeutics currently holds about 17.95 M in cash with (19.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.22. | |
| vTv Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 39.0% of the company outstanding shares are owned by insiders | |
| Latest headline from gurufocus.com: Insider Buying Paul Sekhri Acquires Shares of vTv Therapeutics Inc |
VTv Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in vTv Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to VTv Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know VTv Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as VTv Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading vTv Therapeutics backward and forwards among themselves. VTv Therapeutics' institutional investor refers to the entity that pools money to purchase VTv Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Activest Wealth Management | 2024-06-30 | 50.0 | Parallel Advisors, Llc | 2024-06-30 | 38.0 | Planned Solutions, Inc. | 2024-09-30 | 25.0 | Cornerstone Planning Group Llc | 2024-09-30 | 19.0 | Sunbelt Securities | 2024-06-30 | 15.0 | Bnp Paribas Arbitrage, Sa | 2024-06-30 | 9.0 | Bank Of America Corp | 2024-06-30 | 8.0 | Jpmorgan Chase & Co | 2024-06-30 | 2.0 | Qube Research & Technologies | 2024-06-30 | 1.0 | Samsara Biocapital, Llc | 2024-09-30 | 206.8 K | Fmr Inc | 2024-09-30 | 178.2 K |
Follow VTv Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 37.04 M.Market Cap |
|
Project VTv Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.84) | (1.93) | |
| Return On Capital Employed | (63.91) | (60.72) | |
| Return On Assets | (1.84) | (1.93) | |
| Return On Equity | 0.82 | 0.47 |
When accessing VTv Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures VTv Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of VTv Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in VTv Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of vTv Therapeutics. Check VTv Therapeutics' Beneish M Score to see the likelihood of VTv Therapeutics' management manipulating its earnings.
Evaluate VTv Therapeutics' management efficiency
vTv Therapeutics has return on total asset (ROA) of (0.4148) % which means that it has lost $0.4148 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.6213) %, meaning that it created substantial loss on money invested by shareholders. VTv Therapeutics' management efficiency ratios could be used to measure how well VTv Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.93 in 2024. Return On Capital Employed is likely to gain to -60.72 in 2024. At this time, VTv Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Other is likely to gain to about 23.4 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 10.5 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (8.90) | (9.34) | |
| Tangible Book Value Per Share | (8.90) | (9.34) | |
| Enterprise Value Over EBITDA | (0.59) | (0.62) | |
| Price Book Value Ratio | (0.97) | (1.02) | |
| Enterprise Value Multiple | (0.59) | (0.62) | |
| Price Fair Value | (0.97) | (1.02) | |
| Enterprise Value | 15.1 M | 14.3 M |
The leadership approach at VTv Therapeutics' fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Enterprise Value Revenue 5.3125 | Revenue 1000 K | Revenue Per Share 0.411 | Return On Equity (3.62) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific VTv Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on VTv Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases VTv Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
VTv Therapeutics Corporate Filings
F4 | 19th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 12th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 25th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 23rd of September 2024 Other Reports | ViewVerify |
VTv Therapeutics Earnings per Share Projection vs Actual
VTv Therapeutics Corporate Management
| David III | Sr Counsel | Profile | |
| Vanessa McDade | Chief Officer | Profile | |
| Elizabeth Keiley | Executive Counsel | Profile | |
| Carmen Valcarce | Chief VP | Profile | |
| MD FACC | Executive Chairperson | Profile |
Additional Tools for VTv Stock Analysis
When running VTv Therapeutics' price analysis, check to measure VTv Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VTv Therapeutics is operating at the current time. Most of VTv Therapeutics' value examination focuses on studying past and present price action to predict the probability of VTv Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VTv Therapeutics' price. Additionally, you may evaluate how the addition of VTv Therapeutics to your portfolios can decrease your overall portfolio volatility.